Zimmer Biomet Announces Leadership Transition

Zimmer Biomet Holdings Inc., a provider of musculoskeletal healthcare, announced that David C. Dvorak has stepped down as president and chief executive officer and a member of the Board of Directors, effective today. To assist with the transition, Dvorak will serve in an advisory capacity to the company for a period of time. The Board has appointed Daniel P. Florin, senior vice president and chief financial officer, to serve in the additional role of interim CEO and a member of the Board of Directors until a permanent successor has been named.
 
The Zimmer Biomet Board is retaining a leading executive search firm to identify and evaluate candidates for the permanent CEO role.
 
Dvorak said, “Serving alongside Zimmer Biomet’s dedicated employees over the past 16 years and leading the company as CEO for ten of those years has been a privilege and a highlight of my professional career. Our collective efforts grew employment from approximately 3,000 in 2001 to 18,000 today and built a Fortune 500 company. I am particularly proud of what we have accomplished working together with surgeons and clinicians to help millions of patients globally improve their quality of life.” 
 
Larry C. Glasscock, chairman of the Board of Zimmer Biomet, commented, “During David’s ten-year tenure as CEO, Zimmer Biomet has transformed into a truly global leader in musculoskeletal healthcare. Through a combination of organic growth and strategic acquisitions, Zimmer Biomet’s revenue has doubled and the company has established a leading portfolio of technologies, solutions and personalized services. With this strong platform in place, there is tremendous opportunity for Zimmer Biomet. On behalf of the Board, I thank David for his many important contributions to our company and industry over the years and wish him much success in the future.”
 
Glasscock continued, “We are fortunate to have a leader of Dan’s caliber and experience to step into the CEO role on an interim basis while the Board conducts its search process. Dan’s knowledge of Zimmer Biomet and his achievements here and at other medical device companies make him an excellent choice to support the company through this interim period. We appreciate his willingness to take on this expanded role.”
 
Florin said, “Zimmer Biomet has a talented and dedicated team and an unmatched portfolio. I am honored to assume the Interim CEO role and I look forward to working closely with the Board, senior leadership team and our sales force as we strive to support our customers and enhance stockholder value.”